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ABSTRACT
Background: Chronic lung allograft dysfunction in the
form of bronchiolitis obliterans syndrome (BOS) is the
main cause of death beyond 1-year post-lung
transplantation. The disease-initiating triggers as well
as the molecular changes leading to fibrotic alterations
in the transplanted lung are largely unknown. The aim
of this study was to identify potential early changes in
the extracellular matrix (ECM) in different
compartments of the transplanted lung prior to the
development of BOS.
Methods: Transbronchial biopsies from a cohort of 58
lung transplantation patients at the Copenhagen
University hospital between 2005 and 2006, with or
without development of BOS in a 5-year follow-up,
were obtained 3 and 12 months after transplantation.
Biopsies were assessed for total collagen, collagen
type IV and biglycan in the alveolar and small airway
compartments using Masson’s Trichrome staining and
immunohistochemistry.
Results: A time-specific and compartment-specific
pattern of ECM changes was detected. Alveolar total
collagen (p=0.0190) and small airway biglycan
(p=0.0199) increased between 3 and 12 months after
transplantation in patients developing BOS, while
collagen type IV (p=0.0124) increased in patients
without BOS. Patients with early-onset BOS mirrored
this increase. Patients developing grade 3 BOS showed
distinct ECM changes already at 3 months. Patients
with BOS with treated acute rejections displayed
reduced alveolar total collagen (p=0.0501) and small
airway biglycan (p=0.0485) at 3 months.
Conclusions: Patients with future BOS displayed
distinct ECM changes compared with patients without
BOS. Our data indicate an involvement of alveolar and
small airway compartments in post-transplantation
changes in the development of BOS.
INTRODUCTION
Lung transplantation (ltx) is a life-saving treat-
ment option for patients with severe chronic
pulmonary diseases.1 Unfortunately, about
50% of the patients develop chronic lung allo-
graft dysfunction (CLAD) within 5 years after
transplantation, leading to decreased lung
function and organ failure.2 CLAD is deﬁned
by a persistent decline in forced expiratory
volume in 1 s (FEV1) below 80% of baseline,
while excluding other possible reasons.3 Two
subtypes are known: the more common
obstructive phenotype called bronchiolitis
obliterans syndrome (BOS) and a recently
identiﬁed restrictive phenotype.4–6 The
common theory is that a damage-inducing
event during or after transplantation triggers
an epithelial repair response with activation of
inﬂammatory and non-inﬂammatory media-
tors leading to ﬁbrosis.7 Risk factors for CLAD
are recognised with acute cellular rejection
episodes remaining the most important
one.6 8 However, the damaging insult and the
concrete molecular changes resulting in ﬁbro-
sis remain unknown. After acute cellular rejec-
tion has resolved, transbronchial biopsies seem
normal in routine investigation with appar-
ently no residual damage left.
The present study focuses on BOS. BOS
severity is graded according to the FEV1
decrease (BOS 1: 66–80%, BOS 2: 51–65%,
KEY MESSAGES
▸ Do changes in the extracellular matrix precede
the development of bronchiolitis obliterans syn-
drome after lung transplantation?
▸ Total collagen, collagen type IV and biglycan show
compartment-specific changes after transplant-
ation which distinguish patients who do or do not
develop bronchiolitis obliterans syndrome.
▸ The identification of time-specific and
compartment-specific molecular changes after
transplantation is a precondition for a better under-
standing of disease development in the future.
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BOS 3: <50% FEV1 of baseline).
6 In biopsies, obliterative
bronchiolitis lesions can be found in small airways;
however, these are focal in nature and easily missed.
There is a strong need to investigate molecular changes
leading to BOS with the aim to improve diagnostic tools
and to understand pathological mechanisms, for
example, by gene expression proﬁling and evaluation of
subsets of immune-modulating cells in bronchoalveolar
lavage.9–12
We hypothesise that until now unknown triggers of
BOS lead to changes in the extracellular matrix (ECM),
possibly in different parts of the transplanted lung.
These changes might be signs of ongoing remodelling
processes that, at a later stage, lead to increased suscepti-
bility to BOS.
We analysed the content of total collagen, collagen
type IV (col IV), and biglycan in transbronchial biopsies
of 58 lung transplanted patients with or without BOS,
both at 3 and 12 months post-ltx. We assessed both
alveolar parenchyma and small airways. Changes in
small airways are well described, but there is evidence of
involvement of alveolar tissue in BOS as well.13 14
Collagens are believed to be among the most highly
deposited proteins during ﬁbrosis.15 Col IV is present in
basement membranes (BM) and we focused on the pre-
dominant isoform (α-chain 1/1/2-trimer) in the adult
lung.16–18 Changes in the BM might be directly corre-
lated to epithelial damage. Biglycan is a proteoglycan
with complex functions in tissue homoeostasis due to its
capacity to sequester soluble factors.19 20 Increased bigly-
can was found in central airways and alveolar paren-
chyma of patients with uncontrolled asthma.21
Furthermore, ﬁbroblasts isolated from patients who
developed BOS were shown to be more responsive to
TGF-β1-induced biglycan expression compared with
stable patients.22
The systematic quantiﬁcation of these proteins
revealed a time-speciﬁc and localisation-speciﬁc pattern
of ECM changes, which differed between patients who
did or did not develop BOS.
MATERIALS AND METHODS
Study population
All patients undergoing ltx at Copenhagen University
Hospital (Rigshospitalet, Denmark) in 2005 and 2006
were included in this study (n=60). Therefore, this
patient set is likely to be an unbiased cohort of lung
transplant recipients. This material has been described
previously with an emphasis on regulatory T cells.12
Patient characteristics with a focus on BOS and acute
rejections are summarised in table 1. Online
supplementary ﬁgure S1 depicts the two subpopulations
of patients with early and late onset of BOS.
Two patients died shortly after transplantation.
Fifty-eight patients entered the surveillance follow-up
programme with regular transbronchial biopsies and
lung function measurements. No major bleedings or
pneumothoraxes occurred. Details of the immunosup-
pressive regimen (induction therapy with antithymocyte
globulin, maintenance therapy with cyclosporine and
azathioprine with prednisolone) have been described
previously.12 23 Patients were treated with azithromycin
when diagnosed with BOS.
In the frame of this study, patients were followed for
5 years and assessed whether they did or did not develop
BOS. There was no signiﬁcant difference in the ischae-
mia time between the two groups. Per-protocol surveil-
lance biopsies from 3 and 12 months were analysed
retrospectively. Retrospective analysis does not require
ethical committee approval but the study was approved
by the Danish Data Protection Agency. Biopsies were
scored according to current ISHLT criteria for the diag-
nosis of lung rejection by an experienced pathologist
(CBA).3 Only treated acute cellular rejection episodes
were considered in this study (grade A2 or higher, treat-
ment with methylprednisolone).
Biopsies with an insufﬁcient amount of alveolar tissue
or small airway areas, obviously missing staining due to
biopsy preparation artefacts or with heavily destroyed
tissue morphology, were excluded.
Masson’s Trichrome staining
Masson’s Trichrome staining to assess total collagen
content was performed on 4 µm sections from formalin-
ﬁxed, parafﬁn-embedded biopsies as a routine proced-
ure at the Department of Pathology, Copenhagen
University Hospital, Denmark.
Immunohistochemistry
An immunohistochemistry (IHC) double-staining pro-
cedure visualised col IV and biglycan on 4 µm sections
Table 1 Recipient characteristics
Mean recipient age (years) 42 (range 14–66)
Recipient gender 25 women, 33 men
Transplant type (number of patients)
Single lung 26
Double lung 31
Heart lung 1
Number of patients with n numbers of treated acute
rejection episodes (within 3/12 months post-ltx)
n=0 31/28
n=1 10/14
n=2 14/11
n=3 2/5
Number of patients developing BOS* 28 of 58
Early onset (0.4–1.2 years post-ltx) 15
Late onset (2.3–4.4 years post-ltx) 13
Number of patients (early/late onset) with maximal BOS
grade of*
Grade 1 1/6
Grade 2 1/5
Grade 3 13/2
*Within 5 years post-ltx follow-up.
BOS, bronchiolitis obliterans syndrome; ltx, lung transplantation.
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from formalin-ﬁxed, parafﬁn-embedded biopsies using
the EnVision Doublestain System (K5361, Dako,
Glostrup, Denmark) according to the manufacturer’s
instructions. Single-staining tests for each antibody
showed that the locations for the two proteins were not
overlapping, thereby enabling quantiﬁcation of each
target in the double staining procedure. Antibodies were
assessed for speciﬁcity and optimal antigen retrieval
methods.21 Antigen retrieval was performed with 0.2%
bovine testicular hyaluronidase (Sigma type I-S, buffer
20mM sodium acetate, 150mM sodium chloride, pH 5.2)
for 30 min and subsequently with 20 µg/mL protease
XXIV in PBS (Subtilisin, Carlsberg, Sigma) for 20 min
(both room temperature). Primary antibodies against col
IV α1 chain (Abcam 6586, concentration 1 mg/mL, used
at 1:4000) and biglycan (Atlas antibodies, Uppsala,
Sweden, HPA003157, concentration 0.1 mg/mL, used at
1:1750) were incubated for 1 hour at room temperature.
Secondary antibodies produced brown (col IV) or red
(biglycan) precipitates. Sections were counterstained
with Mayer’s haematoxylin for visualisation of nuclei.
Tissue analysis and quantification
Sections were scanned using the ScanScope slide scanner
(Aperio, Vista, California, USA). Masson’s Trichrome
staining and extent of immunoreactivity against col IV
and biglycan were quantiﬁed using the histology pro-
gramme Visiomorph (Visiopharm, Hoersholm,
Denmark). After deﬁning the categories (positive stain-
ing, unstained tissue, background), the programme
quantiﬁed the respective areas, thus allowing exclusion of
the background so that air spaces were excluded from
analysis. Satisfactory discrimination of positive col IV
(brown) and biglycan (red) staining was checked in all
samples. The different compartments were delineated
manually and analysed separately.
Alveolar tissue: Included were clearly discernible alveo-
lar regions. Other structures (cartilage, muscle, vessels
larger than ∼75 µm and cell accumulations in the
alveoli) were carefully excluded. The percentage of posi-
tively stained area was obtained by dividing the stained
area by the total tissue area, multiplied by 100.
Small airways: Small airways were deﬁned by the absence
of cartilage and submucosal glands. The analysed area was
deﬁned as the area from below the epithelial layer (includ-
ing the BM) to (but not including) the airway smooth
muscle. Only airways where muscle was visible, or where
extrapolation between streaks of muscles was possible,
were analysed. Epithelial cells or an intact BM had to be
visible to ensure complete areas. Quantiﬁcation of positive
staining was performed by relating the area of positive
staining to the length of the epithelium.
All tissue analyses as well as IHC were performed in a
blinded fashion by one of the investigators (CM).
Statistical analysis
Data analyses were performed using GraphPad Prism
V.6.05 (GraphPad Software, San Diego, California, USA)
and are presented as scatter dot plots with median
values. The non-parametric Wilcoxon matched-pairs
signed-rank test was used for paired data; the non-
parametric Mann-Whitney test was used for unpaired
analysis as indicated in the ﬁgures.
RESULTS
General distribution of total collagen, col IV and biglycan
Masson’s Trichrome staining visualised collagen in the
airways, often clearly depicting the reticular BM, but
also reaching deeper (see online supplementary ﬁgure
S2A). It stained interstitial ECM (see online
supplementary ﬁgure S2C) as well as the vascular adven-
titia (see online supplementary ﬁgure S2B,C). Alveolar
septa stained variably, from thick ECM bundles to ﬁne
ﬁbrillar structures (see online supplementary ﬁgure S2B
and ﬁgure 1A’–A’’’).
Col IV was detected in the BM of alveolar septa (see
online supplementary ﬁgure S2F and ﬁgure 1B’–B’’’),
airways (see online supplementary ﬁgure S2E and
ﬁgure 1C’–C’’’), capillaries (see online supplementary
ﬁgure S2F), and muscle ﬁbres in the airway musculature
and in big and small vessels (see online supplementary
ﬁgure S2F,G).
Biglycan was detected in subepithelial regions of
airways, often accumulating close to the BM (see online
supplementary ﬁgure S2E and ﬁgure 1C’–C’’’), in the
adventitia of larger vessels (see online supplementary
ﬁgure S2G) and around small vessels (see online
supplementary ﬁgure S2F). Alveolar septa showed bigly-
can in patchy or ﬁne structures (see online
supplementary ﬁgure S2F and ﬁgure 1B’–B’’’). Staining
of the pericellular matrix of cartilage conﬁrmed the
speciﬁcity of the biglycan antibody (see online
supplementary ﬁgure S2D).24 Omitting primary anti-
bodies resulted in total absence of staining, thus con-
ﬁrming the speciﬁcity of the secondary antibodies (see
online supplementary ﬁgure S2H).
Compartment-specific increase in total collagen, col IV
and biglycan between 3 and 12 months after ltx
On the group level, total collagen and col IV increased
in the alveolar compartment, but not in the small
airways, between 3 and 12 months post-ltx (ﬁgure 1A, B;
Wilcoxon matched-pairs test, p=0.0247 and p=0.0024,
respectively). In contrast, biglycan increased in the small
airways, but not in the alveolar compartment (ﬁgure 1C;
Mann-Whitney test, p=0.0475). Representative pictures
are shown in ﬁgure 1, while enlarged ﬁgures are shown
in online supplementary ﬁgures S3A–C.
Patients with BOS displayed compartment-specific post-ltx
changes compared with patients without BOS
On the group level, patients with BOS showed increased
alveolar total collagen between 3 and 12 months
(ﬁgure 2A; Wilcoxon matched-pairs test, p=0.019),
while patients without BOS did not (ﬁgure 2A’;
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p=0.784). The same pattern was observed for biglycan,
however, only in the small airways (ﬁgure 2C, C’;
Mann-Whitney test, p=0.0199 for patients with BOS,
p=0.8514 for patients without BOS). On the other hand,
patients who did not develop BOS displayed signiﬁcantly
increased alveolar col IV (ﬁgure 2B’; Wilcoxon matched-
pairs test, p=0.0124) while it only slightly increased in
patients developing BOS (ﬁgure 2B; p=0.0730). No
difference could be observed when comparing patients
with or without BOS at 3 or 12 months, respectively.
Biopsies from the same patient at 3 and 12 months
post-ltx allowed for comparisons of ECM changes over
time within each individual (ﬁgure 2A’’, B’’, C’’).
Depicted is the difference of total collagen, col IV and
biglycan per individual (value at 12 months minus value
at 3 months). For small airway biglycan, a distinct
Figure 1 ECM changes between 3 and 12 months post-transplantation in different pulmonary compartments. Total collagen (A)
and col IV (B) were increased in the alveoli, and biglycan (C) was increased in the small airways (3 vs 12 months, total collagen
and col IV: Wilcoxon matched-pairs test, biglycan: Mann-Whitney test). Data are shown as scatter dot plots with median values.
Open symbols in A–C indicate the individual biopsies shown in the pictures. Representative pictures of biopsies with low,
medium and high staining intensity for alveolar total collagen (A’–A’’’), alveolar (B’–B’’’) and small airway biglycan/col IV (C’–C’’’).
Scale bar=50µm, Masson’s Trichrome total collagen: blue (→), col IV: brown (Δ), biglycan: red (►). Blue lines indicate regions of
interest for quantification of the staining in the small airways. Col IV, collagen type IV; ECM, extracellular matrix; IHC,
immunohistochemistry.
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individual difference between patients developing BOS
and patients without BOS was observed (Mann-Whitney
test, p=0.0121; ﬁgure 2C’’).
Patients with early-onset BOS showed distinct ECM
changes between 3 and 12 months
In our study, patients with BOS exhibited early-onset
BOS (within 1.2 years) and late-onset BOS (2.3 years or
later; table 1 and online supplementary ﬁgure S1).
Thirteen of 15 early-onset patients proceeded to BOS
grade 3 within the 5-year follow-up, while 2 of 13
late-onset patients developed BOS grade 3 in the same
time frame.
Only patients with early-onset BOS showed increased
alveolar total collagen and col IV (ﬁgure 3A, B; Wilcoxon
matched-pairs test, p=0.0327 and p=0.0391, respectively)
and small airway biglycan (ﬁgure 3C; Mann-Whitney test,
p=0.025) between 3 and 12 months post-ltx.
BOS severity and early ECM changes
Patients proceeding to BOS grade 3 showed higher
content of alveolar total collagen (ﬁgure 3D) and
small airway col IV (ﬁgure 3E) at 3 months post-ltx
compared with patients who had a maximum BOS
grade of 1 or 2 (Mann-Whitney test, p=0.0362 and
p=0.0343, respectively).
Figure 2 ECM changes between 3 and 12 months post-ltx in patients with or without BOS in the different pulmonary
compartments. Changes in total alveolar collagen, alveolar col IV and small airway biglycan between 3 and 12 months post-ltx in
patients developing BOS (A, B, C) and patients without BOS (A’, B’, C’) on the group level. Difference in total alveolar collagen
(A’’), alveolar col IV (B’’) and small airway biglycan (C’’) for each individual patient between 3 and 12 months post-ltx. Scatter dot
plots are shown with median values. Statistical tests were Wilcoxon matched-pairs test in A, A’, B, B’ and Mann-Whitney test in
A’’, B’’, C–C’’. BOS, bronchiolitis obliterans syndrome; col IV, collagen type IV; ECM, extracellular matrix; ltx, lung transplantation.
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Acute rejection episodes, early compartment-specific ECM
changes and later development of BOS
Patients who later developed BOS and suffered from
treated acute rejections within 3 months post-ltx showed
lower total alveolar collagen (ﬁgure 4A) and small
airway biglycan (ﬁgure 4C) at 3 months post-ltx, com-
pared with patients with BOS who experienced no
treated acute rejections (Mann-Whitney test, p=0.004
and p=0.0266, respectively). This was not observed for
patients without BOS (ﬁgure 4A’, C’). When directly
comparing the alveolar collagen content and the small
airway biglycan content in patients developing BOS com-
pared with patients without BOS (both groups with
treated acute rejection within 3 months), this decrease
was observed as well (ﬁgure 4A’’, C’’; Mann-Whitney test,
p=0.0501 and p=0.0485, respectively).
In contrast, a difference in alveolar col IV at 3 months
was observed in patients who did not experience treated
acute rejection episodes (ﬁgure 4B’’). Here, patients
who developed BOS showed increased alveolar col IV
content compared with patients without BOS
(Mann-Whitney test, p=0.0492). There was no difference
when comparing patients with or without treated acute
rejections (ﬁgure 4B, B’).
No differences were observed with regard to total col-
lagen, col IV and biglycan content at 12 months in
relation to the number of treated acute rejections until
12 months post-ltx (data not shown).
DISCUSSION
Identifying molecular changes leading to BOS is essen-
tial for understanding disease development. We mapped
total collagen, col IV and biglycan in transbronchial
biopsies and related the results to later development of
BOS and clinical parameters. We identiﬁed a location-
speciﬁc and time-speciﬁc pattern of these ECM proteins.
To the best of our knowledge, this is the ﬁrst report
identifying early ECM changes associated with later BOS
development. The ﬁndings do not yet allow suggestion
of any causal mechanism.
The main ﬁndings of our study were: (1) alveolar and
small airway compartments displayed different post-ltx
changes; (2) patients with BOS showed different post-ltx
changes compared with patients without BOS; (3)
patients with early-onset BOS showed increased BOS
severity and distinct, early ECM changes; and (4) early
acute rejection episodes coincided with early ECM
changes in patients developing BOS.
Localisation of ECM changes in distinct compartments
Between 3 and 12 months post-ltx, we observed changes
in the content of total collagen and col IV in the
Figure 3 Subgrouping of the patient population according to early-onset/late-onset BOS and maximal BOS grade. Increase in
total alveolar collagen (A), alveolar col IV (B) and small airway biglycan (C) in early-onset patients with BOS between 3 and
12 months post-ltx. Patients proceeding to BOS grade 3 within the follow-up showed increased total alveolar collagen (D) and
small airway col IV (E) compared with patients with a maximum of BOS grade 1 or 2. Scatter dot plots are shown with median
values. Statistical tests were Wilcoxon matched-pairs test in A–B and the Mann-Whitney test in C–E. BOS, bronchiolitis obliterans
syndrome; col IV, collagen type IV; ltx, lung transplantation.
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alveolar, but not the small airway, compartment. In con-
trast, biglycan changed in the small airways, but not in
the alveoli. This pattern was consistent, both when ana-
lysing the whole patient set and when relating the data
to subgroups according to later BOS status and occur-
rence of acute rejection (ﬁgures 1–4). This is interesting
since changes in the small airways are well described in
BOS while alveolar changes are less recognised due to
inconspicuousness in routine histopathological assess-
ments.3 13 14 General changes, irrespective of BOS, have
been described before, probably being part of an adap-
tation response.13 22 25
We also observed differences within the ECM. The BM
is a thin, sheet-like specialisation of the ECM. Col IV, a
BM marker, was found to increase in the alveoli between
3 and 12 months in patients who remained BOS-free.
Total collagen and biglycan, proteins of the interstitial
ECM, increased in patients who developed BOS.
Summarising, our data argue for distinct post-ltx mechan-
isms in different parts of the transplanted lung, possibly
playing a part in BOS pathogenesis.
The time aspect in post-ltx changes of the ECM and
development of BOS
We did not ﬁnd a difference at 3 or 12 months in the
content of total collagen, col IV or biglycan when directly
comparing all patients who did, or did not, develop BOS.
However, differences became apparent when focusing on
changes between 3 and 12 months (ﬁgure 2). This
underlines the importance of the time aspect when inves-
tigating BOS as well as the value of paired data. The data
presented for total collagen and col IV were analysed
Figure 4 Treated acute rejection and ECM changes at 3 months in patients with/without BOS. Depicted are changes in total
alveolar collagen (A, A’), alveolar col IV (B, B’) and small airway biglycan (C, C’) at 3 months when comparing patients with/
without BOS who did or did not experience treated acute rejections within 3 months post-ltx. (A’’, B’’ and C’’) Direct comparisons
between patients developing BOS and patients without BOS at 3 months. Scatter dot plots are shown with median values. Data
were analysed using the Mann-Whitney test. BOS, bronchiolitis obliterans syndrome; col IV, collagen type IV; ECM, extracellular
matrix; ltx, lung transplantation.
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using the Wilcoxon matched-pairs test when applicable.
Owing to a lack of paired data, this was not possible for
biglycan and the Mann-Whitney test was used. However,
we ﬁnd the data convincing when plotting the individual
differences (ﬁgure 2C’’).
The time factor is also illustrated by the known hetero-
geneity in onset and disease progression of patients
with BOS,6 26 27 which we also see in our patient set
(table 1). Patients with early-onset BOS and with a high
BOS grade displayed distinct ECM changes (ﬁgure 3).
The goal of studies like ours is to identify predictive
markers. Interestingly, patients with future BOS dis-
played decreased alveolar total collagen and small airway
biglycan at 3 months when having experienced treated
acute rejections, compared with patients with BOS who
did not have these (ﬁgure 4). This relation could not be
seen for patients without BOS.
These post-ltx changes are remarkable when consider-
ing the crucial effect of the ECM on lung architecture
and cellular behaviour.28 Collagens are low-turnover pro-
teins but their deposition can change with appropriate
stimuli as observed in wound healing.29 30 Proteoglycans
like biglycan can react to changes in the microenviron-
ment, for example, by being cleaved and releasing
ﬁbrotic mediators or by affecting cell migration.20 31 32
Granzyme B, an inﬂammatory serine protease whose
expression increases in BAL during acute rejection,
cleaves biglycan, thereby releasing active TGF-β1, a
major inducer of ﬁbrotic processes.15 33 34
Our data on ECM protein changes after ltx are in
good agreement with the current hypothesis of BOS
development.7 Early post-ltx events, for example, during
acute rejection, lead to tissue damage that might be illu-
strated by the decrease in ECM proteins at 3 months in
patients with BOS with acute rejections. This is counter-
acted by repair mechanisms leading to ECM deposition
as seen in our study by an increase in total alveolar colla-
gen and small airway biglycan between 3 and 12 months
in patients with future BOS. Finally, this process might
become uncontrolled, possibly leading to ﬁbrosis.
The mechanistic link between pre-ltx, peri-ltx and
post-ltx events; the occurrence of acute rejection epi-
sodes; and the development of chronic rejection is until
now not established. While there are a multitude of
studies examining cellular immunological events, includ-
ing both the innate and the adaptive immune system,
data conclusively describing the effect on the ECM
molecules are still scarce.35 36 We speculate that the
massive inﬂux of immune cells during acute rejection,
secreting various cytokines, creates a catabolic environ-
ment, most likely by production and activation of matrix
metalloproteinases (MMP). Elevated levels of MMP-8
and MMP-9, proteases degrading collagens, as well as
proteoglycans like biglycan, have been shown to precede
BOS.37–39 These processes might be enhanced by a pos-
sible protein catabolic effect of methylprednisolone
during treatment of acute rejection episodes.40 On a
histological level, acute rejections resolve completely;
consequently, a restoration of tissue homoeostasis must
occur. Macrophages are cells which potentially might
link together acute and chronic rejection.41 While acti-
vated M1-like macrophages are involved in acute tissue
inﬂammation, there might be a polarisation towards
M2-like macrophages in the later resolving phase.36 42 43
Interestingly, certain M2 macrophage subtypes, most
prominently M2c macrophages, have been implicated to
actively take part in ﬁbrotic processes.44 45 However,
more research effort is needed to understand processes
leading to the development of CLAD.
Our study provides a proof of concept on how to
follow post-transplantation events in the ECM on a
molecular level. We suggest using this approach further
in larger independent studies involving patient cohorts
from different transplantation centres.
This study is based on small forceps biopsies, which
increases the feasibility for all lung transplant centres to
implement this technique, but limits conclusions one
may draw on the whole lung. This bigger picture is the
aim of studies visualising post-ltx changes in explants
with advanced imaging techniques.46 47
Our study emphasises the importance of ECM
changes possibly leading to BOS, where time is an
important factor as well as the localisation to distinct
compartments of the transplanted lung.
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